Csl Ltd ADR (CSLLY)

$79.20 +2.14 (2.78%)
Market Cap 74.63B
Revenue (ttm) 14.80B
Net Income (ttm) 2.64B
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 24.19
Profit Margin 17.85%
Debt to Equity Ratio 0.58
Volume 53,600
Avg Vol 81,858
Day's Range N/A - N/A
Shares Out 968.42M
Stochastic %K 67%
Beta 0.80
Analysts Strong Sell
Price Target $100.00

Company Profile

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment o...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9389 1911
Fax: 61 3 9389 1434
Address:
655 Elizabeth Street, Melbourne, Australia
LewisDaKat
LewisDaKat Jun. 17 at 12:25 AM
News Article U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start https://marketwirenews.com/news-releases/u-s-food-and-drug-administration-approves-csl-s-ande-6800974205429602.html $CSLLY
0 · Reply
PenkeTrading
PenkeTrading Feb. 12 at 6:42 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CSL Ltd. Is that bullish or bearish? $CSLLY #RsiOversold #PINK
0 · Reply
George_Carlin_Lives
George_Carlin_Lives Feb. 11 at 7:25 AM
$CSLLY The market is punishing CSL for making money
0 · Reply
reg0sce
reg0sce Jan. 10 at 2:30 AM
$CSLLY $CSLLY Use to be a good company, but piss poor management has ran it in the ground. Unloading this turd!!
0 · Reply
Jeko44
Jeko44 Jan. 6 at 8:32 PM
$AKBA I don’t know if $CSLLY can afford us. Their market cap is only $85B…😉
0 · Reply
LewisDaKat
LewisDaKat Oct. 17 at 10:55 AM
$CSLLY $CSLLY Nhttps://marketwirenews.com/news-releases/csl-vifor-and-travere-therapeutics-announce-swissmed-8036968104308380.html ews out CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy
0 · Reply
swingingtech
swingingtech Oct. 17 at 7:04 AM
$TVTX $CSL $CSLLY https://wallstreetwaves.com/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-sparsentan-for-t
0 · Reply
reg0sce
reg0sce Aug. 18 at 6:27 PM
$CSLLY 5 years and still is the same spot, just a stall lame stock… Time to move on’
0 · Reply
Jeko44
Jeko44 Jul. 12 at 9:13 PM
$CSLLY another strong price gain and volume here today and the last 3 months.
0 · Reply
Jeko44
Jeko44 Jul. 11 at 1:57 PM
$AKBA $CSLLY is also up 3% today. They must be happy, too 🙂
0 · Reply
Latest News on CSLLY
No data available.
LewisDaKat
LewisDaKat Jun. 17 at 12:25 AM
News Article U.S. Food and Drug Administration Approves CSL's ANDEMBRY (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Patients From the Start https://marketwirenews.com/news-releases/u-s-food-and-drug-administration-approves-csl-s-ande-6800974205429602.html $CSLLY
0 · Reply
PenkeTrading
PenkeTrading Feb. 12 at 6:42 AM
I found you an Oversold RSI (Relative Strength Index) on the daily chart of CSL Ltd. Is that bullish or bearish? $CSLLY #RsiOversold #PINK
0 · Reply
George_Carlin_Lives
George_Carlin_Lives Feb. 11 at 7:25 AM
$CSLLY The market is punishing CSL for making money
0 · Reply
reg0sce
reg0sce Jan. 10 at 2:30 AM
$CSLLY $CSLLY Use to be a good company, but piss poor management has ran it in the ground. Unloading this turd!!
0 · Reply
Jeko44
Jeko44 Jan. 6 at 8:32 PM
$AKBA I don’t know if $CSLLY can afford us. Their market cap is only $85B…😉
0 · Reply
LewisDaKat
LewisDaKat Oct. 17 at 10:55 AM
$CSLLY $CSLLY Nhttps://marketwirenews.com/news-releases/csl-vifor-and-travere-therapeutics-announce-swissmed-8036968104308380.html ews out CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI (sparsentan) for the treatment of IgA Nephropathy
0 · Reply
swingingtech
swingingtech Oct. 17 at 7:04 AM
$TVTX $CSL $CSLLY https://wallstreetwaves.com/csl-vifor-and-travere-therapeutics-announce-swissmedic-approval-of-filspari-sparsentan-for-t
0 · Reply
reg0sce
reg0sce Aug. 18 at 6:27 PM
$CSLLY 5 years and still is the same spot, just a stall lame stock… Time to move on’
0 · Reply
Jeko44
Jeko44 Jul. 12 at 9:13 PM
$CSLLY another strong price gain and volume here today and the last 3 months.
0 · Reply
Jeko44
Jeko44 Jul. 11 at 1:57 PM
$AKBA $CSLLY is also up 3% today. They must be happy, too 🙂
0 · Reply
falconfly1
falconfly1 Jul. 7 at 10:43 PM
$EYEN $SHPH and $ANIP and $CSLLY and $GSK What is new and opportunity in $EYEN? 1 - Insider bought 1.5 million shares in July and paid 1 Million dollars 2 - Vanguard biggest institution in the world bought 5 million dollars for a call option 3 - First FDA MydCombi selling from April 2024, and they have a contract with Vision Source biggest Private Practice Optometrists in the USA and Canada. Vision Source multi a billion company. 4 - Second FDA's strongest eyedrop sales start the first of August and are expected to generate 15 to 40 million per quarter. 5 - 8 or 9 August earnings call, and it should be good. 6 - MicroPine and MicroLine are unmet need eyedrops for children and the result is coming in Q4 2024.
1 · Reply
Jeko44
Jeko44 Jul. 3 at 2:08 PM
$CSLLY the last time csl was this close to $100 was February…looks like it’s time for a break above
0 · Reply
Jeko44
Jeko44 Mar. 27 at 6:46 PM
$CSLLY still
0 · Reply
Jeko44
Jeko44 Mar. 3 at 10:51 PM
$CSLLY
0 · Reply
Financhill
Financhill Jan. 17 at 10:40 PM
$CSLLY is rated a Sell since January 16, 2024 and is 28% below its median level.
0 · Reply
Stock_Titan
Stock_Titan Jan. 3 at 1:00 PM
$CSLLY CSL Behring Announces Availability of Hizentra® (Immune Globulin Subcutaneous [Human] 20% Liquid) 10g Prefilled Syringe
0 · Reply
DonCorleone77
DonCorleone77 Dec. 21 at 1:10 PM
$ARCT $CSLLY Arcturus Therapeutics and CSL' ARCT-154 shows superior immunogenicity Arcturus Therapeutics and CSL announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty. ARCT-154 results were achieved with one-sixth the dose of Comirnaty. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events. The study was conducted in partnership with Meiji Seika Pharma, a global health company based in Japan. The phase 3 study results with ARCT-154 were used to support the approval of ARCT-154 for primary immunization and as a booster dose in Japan in November of this year....
0 · Reply
DonCorleone77
DonCorleone77 Dec. 21 at 1:08 PM
$ARCT $CSLLY Arcturus Therapeutics, CSL publish data on booster dose of ARCT-154 CSL and Arcturus Therapeutics announced the publication in Lancet Infectious Diseases of a Phase 3 study showing that a booster dose of ARCT-154, a novel, self-amplifying messenger RNA, or sa-mRNA, vaccine, elicited a numerically higher immune response against the original Wuhan-Hu-1 virus strain, and a superior immune response against Omicron BA.4/5 subvariant of SARS-CoV-2 virus compared to a booster dose of the conventional mRNA vaccine Comirnaty. ARCT-154 results were achieved with one sixth the dose of Comirnaty. The study included healthy adults initially immunized with two doses of an mRNA vaccine; and then a third dose of Comirnaty at least three months prior to the booster dose of either ARCT-154 or Comirnaty in the study. Both vaccines were well-tolerated, with no causally associated severe or serious adverse events. The study was conducted in partnership with Meiji Seika Pharma...
0 · Reply
Stock_Titan
Stock_Titan Dec. 21 at 1:00 PM
$CSLLY $ARCT CSL and Arcturus Therapeutics' ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
0 · Reply
Stock_Titan
Stock_Titan Dec. 21 at 1:00 PM
$ARCT $CSLLY CSL and Arcturus Therapeutics’ ARCT-154 Demonstrates Non-Inferiority to Original Strain and Superior Immunogenicity to Omicron BA.4/5 Variant Compared to First-Generation mRNA Vaccine Booster
0 · Reply
swingingtech
swingingtech Dec. 14 at 5:30 PM
$ARCT $CSLLY Phase 1 of their CF drug passed! https://wallstreetwaves.com/arcturus-therapeutics-revolutionary-lung-disease-treatment-gets-analysts-excited/
0 · Reply